Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [8]. Group 2: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the FDA regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [7]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].
TLX INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals